A 2015 study published in Nature found that by harnessing genetic data to support the selection of candidate drugs, researchers could double their success rates. Given that only around 10% of clinical programs ultimately result in an approved drug, this has significant implications for how trials are designed and executed. Using genetic data can meaningfully improve success rates in drug development.
Patient registries serve as repositories of genetic information that can be used during precision medicine trials to help us better understand medical conditions and why people react to treatments differently. Understanding what patient registries are, where they create operational value, and where they introduce risk is foundational to using them effectively in precision medicine programs.
Genetic patient registries, also known as disease or clinical data registries, are structured databases designed to house comprehensive genetic and clinical information about patients with specific medical conditions. These registries act as purpose-driven collections of data, organized to serve predetermined scientific, clinical, or policy objectives. A registry will usually capture patients' clinical statuses, medical histories, laboratory results, and more. Some examples of patient registries include those focused on rare diseases, cancer subtypes, or primary immune deficiencies.
There are two general categories of registries that are relevant in this context. Contact registries help connect patients to clinical trials and researchers to patients interested in furthering research. Natural history study registries collect information about a disease from both a patient and clinical perspective, informing every stage of the therapy development process. In precision medicine, both types play distinct roles: contact registries accelerate recruitment, while natural history registries provide the longitudinal data needed to characterize disease progression and define meaningful clinical endpoints.
The purpose of patient registries is to assist healthcare practitioners in formulating optimal treatment strategies for individual patients or specific groups. It is important to note that registries are observational rather than experimental. Unlike clinical trials, they do not investigate a new therapy. Instead, they are based on the patient's actual experience and current medical care. They can also:
Registries can be established by a range of stakeholders, including patient advocacy groups, clinicians, academic researchers, pharmaceutical companies, and biotechnology companies. The value of the data collected in a registry increases when multiple stakeholders collaborate on its design and governance. For precision medicine programs, this means that registry data is most useful when it reflects input from both the clinical and patient perspectives.
Using genetic patient registries speeds up patient recruitment, screening, and enrollment into precision medicine trials through:
Registries are particularly valuable in rare disease contexts, where the following compounding challenges make traditional recruitment approaches insufficient:
In these situations, a well-maintained registry provides a foundation for trial design, patient identification, and longitudinal data collection that would otherwise need to be built from scratch for each new program.
While genetic patient registries have many benefits, they can also pose challenges for pharmaceutical and biotech companies seeking to advance precision medicine:
Addressing these challenges requires coordinated effort across data integration, regulatory strategy, and ethical data governance. For sponsors running precision medicine programs, the ability to work with registry data effectively depends on having systems that can manage these complexities within a compliant and auditable framework.
Genetic patient registries contain sensitive information about individuals' genetic makeup, raising concerns related to privacy, consent, and data security. A robust informed consent process is one of the most important elements of creating or using a registry. This requires transparency about what data is collected, how it will be used, and what risks may be involved. The tension between collective research benefit and individual rights over genetic data is real and unresolved. Questions about genetic information ownership and control must be addressed directly for patient registries to function ethically. This includes clear policies on data access, retention, secondary use, and the circumstances under which participants can withdraw their information.
Genetic patient registries are a foundational component of precision medicine infrastructure. They reduce the operational cost of patient identification, accelerate screening, and provide the longitudinal data needed to design effective trials. They also introduce real challenges around data fragmentation, regulatory compliance, and ethical governance that must be addressed systematically.
For sponsors and research teams working in genetically defined or rare disease populations, the question is not whether registries are useful but whether the systems around them are designed to handle the complexity they introduce. Transparency, informed consent, and rigorous data security are not optional layers. They are structural requirements for any registry-enabled program to function at scale.
To learn about how Sano can help establish patient registries, get in touch.